Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462576 · ClinicalTrials.gov registry record
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
A clinical trial, sponsored by Meridian Bioscience.
- Terminated
- Registry status
- 199
- Enrollment target
NCT03462576 is a clinical trial that was terminated before completion, run by Meridian Bioscience. The registered enrollment target is 199 participants.
The verdict
NCT03462576 was terminated before completion, sponsored by Meridian Bioscience.
- TERMINATED
- Registry status
- 199 participants
- Enrollment target
Study Summary
This study is a companion protocol that will use the data generated by Conatus' study of emricasan under protocol IDN-6556-17.The IDN-6556-17 study is a Phase 2, multicenter, double-blind, placebo-controlled trial of Emricasan in subjects with decompensated non-alcoholic steatohepatitis (NASH) cirrhosis.
Interventions
- DRUG Placebo oral capsule
- DRUG Emricasan
- COMBINATION_PRODUCT Methacetin Breath Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2019-07-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03462576
The ClinicalTrials.gov registry entry for NCT03462576 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03462576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03462576 about?
NCT03462576 is a clinical study titled "Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17". This study is a companion protocol that will use the data generated by Conatus' study of emricasan under protocol IDN-6556-17.The IDN-6556-17 study is a Phase 2, multicenter, double-blind, placebo-controlled trial of Emricasan in subjects with decompensated non-alcoholic steatohepatitis (NASH) cirrh...
What is the current status of trial NCT03462576?
This trial is currently terminated. The enrollment target is 199 participants. The study started on 2017-06-28. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03462576?
The interventions under investigation include: Placebo oral capsule (DRUG), Emricasan (DRUG), Methacetin Breath Test (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03462576?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.